nodes	percent_of_prediction	percent_of_DWPC	metapath
Raloxifene—AOX1—Methotrexate—lung cancer	0.106	0.194	CbGbCtD
Raloxifene—CYP19A1—Paclitaxel—lung cancer	0.0948	0.173	CbGbCtD
Raloxifene—CYP2B6—Irinotecan—lung cancer	0.0386	0.0703	CbGbCtD
Raloxifene—CYP2C8—Erlotinib—lung cancer	0.0323	0.059	CbGbCtD
Raloxifene—CYP2B6—Cisplatin—lung cancer	0.0314	0.0573	CbGbCtD
Raloxifene—CYP2C8—Paclitaxel—lung cancer	0.0296	0.054	CbGbCtD
Raloxifene—CYP3A4—Topotecan—lung cancer	0.0242	0.0442	CbGbCtD
Raloxifene—CYP2C8—Etoposide—lung cancer	0.0234	0.0427	CbGbCtD
Raloxifene—CYP3A4—Gefitinib—lung cancer	0.0222	0.0405	CbGbCtD
Raloxifene—CYP3A4—Teniposide—lung cancer	0.0215	0.0392	CbGbCtD
Raloxifene—CYP2B6—Doxorubicin—lung cancer	0.0211	0.0384	CbGbCtD
Raloxifene—CYP3A4—Vinorelbine—lung cancer	0.0171	0.0312	CbGbCtD
Raloxifene—CYP3A4—Crizotinib—lung cancer	0.0136	0.0248	CbGbCtD
Raloxifene—CYP3A4—Erlotinib—lung cancer	0.0131	0.0239	CbGbCtD
Raloxifene—CYP3A4—Paclitaxel—lung cancer	0.012	0.0219	CbGbCtD
Raloxifene—CYP3A4—Irinotecan—lung cancer	0.0118	0.0216	CbGbCtD
Raloxifene—CYP3A4—Vinblastine—lung cancer	0.0105	0.0192	CbGbCtD
Raloxifene—CYP3A4—Etoposide—lung cancer	0.00948	0.0173	CbGbCtD
Raloxifene—CYP3A4—Docetaxel—lung cancer	0.00868	0.0158	CbGbCtD
Raloxifene—CYP3A4—Doxorubicin—lung cancer	0.00647	0.0118	CbGbCtD
Raloxifene—ESR2—mammary gland—lung cancer	0.00198	0.0871	CbGeAlD
Raloxifene—EBP—Azacitidine—Gemcitabine—lung cancer	0.00177	1	CbGdCrCtD
Raloxifene—SIGMAR1—mammary gland—lung cancer	0.00153	0.0675	CbGeAlD
Raloxifene—ESR1—mammary gland—lung cancer	0.00135	0.0596	CbGeAlD
Raloxifene—ESR2—respiratory system—lung cancer	0.00132	0.058	CbGeAlD
Raloxifene—CYP2C8—mammary gland—lung cancer	0.00112	0.0491	CbGeAlD
Raloxifene—ESR2—epithelium—lung cancer	0.0011	0.0485	CbGeAlD
Raloxifene—AOX1—bronchus—lung cancer	0.00104	0.046	CbGeAlD
Raloxifene—AOX1—trachea—lung cancer	0.000937	0.0413	CbGeAlD
Raloxifene—ESR1—respiratory system—lung cancer	0.000903	0.0397	CbGeAlD
Raloxifene—AOX1—cardiac atrium—lung cancer	0.000881	0.0388	CbGeAlD
Raloxifene—SIGMAR1—bronchus—lung cancer	0.00084	0.037	CbGeAlD
Raloxifene—SIGMAR1—trachea—lung cancer	0.000754	0.0332	CbGeAlD
Raloxifene—ESR1—epithelium—lung cancer	0.000754	0.0332	CbGeAlD
Raloxifene—SIGMAR1—cardiac atrium—lung cancer	0.000709	0.0312	CbGeAlD
Raloxifene—ESR2—lung—lung cancer	0.0007	0.0308	CbGeAlD
Raloxifene—AOX1—lung—lung cancer	0.000674	0.0297	CbGeAlD
Raloxifene—CYP2B6—respiratory system—lung cancer	0.000667	0.0294	CbGeAlD
Raloxifene—SIGMAR1—bone marrow—lung cancer	0.000598	0.0263	CbGeAlD
Raloxifene—CYP2B6—bronchus—lung cancer	0.000549	0.0242	CbGeAlD
Raloxifene—SIGMAR1—lung—lung cancer	0.000542	0.0239	CbGeAlD
Raloxifene—HTR2B—lung—lung cancer	0.000541	0.0238	CbGeAlD
Raloxifene—ESR1—lung—lung cancer	0.000479	0.0211	CbGeAlD
Raloxifene—ESR2—lymph node—lung cancer	0.000479	0.0211	CbGeAlD
Raloxifene—AOX1—lymph node—lung cancer	0.000461	0.0203	CbGeAlD
Raloxifene—CYP19A1—lymph node—lung cancer	0.000377	0.0166	CbGeAlD
Raloxifene—SIGMAR1—lymph node—lung cancer	0.000371	0.0163	CbGeAlD
Raloxifene—HTR2B—lymph node—lung cancer	0.00037	0.0163	CbGeAlD
Raloxifene—CYP2B6—lung—lung cancer	0.000354	0.0156	CbGeAlD
Raloxifene—ESR1—lymph node—lung cancer	0.000328	0.0144	CbGeAlD
Raloxifene—Hyperhidrosis—Irinotecan—lung cancer	0.000263	0.00101	CcSEcCtD
Raloxifene—Pharyngitis—Docetaxel—lung cancer	0.000262	0.001	CcSEcCtD
Raloxifene—Dizziness—Vinblastine—lung cancer	0.000262	0.001	CcSEcCtD
Raloxifene—Urinary tract disorder—Docetaxel—lung cancer	0.000261	0.001	CcSEcCtD
Raloxifene—Muscle spasms—Paclitaxel—lung cancer	0.000261	0.000999	CcSEcCtD
Raloxifene—Diarrhoea—Erlotinib—lung cancer	0.000261	0.000998	CcSEcCtD
Raloxifene—Body temperature increased—Vinorelbine—lung cancer	0.00026	0.000997	CcSEcCtD
Raloxifene—Abdominal pain—Vinorelbine—lung cancer	0.00026	0.000997	CcSEcCtD
Raloxifene—Oedema peripheral—Docetaxel—lung cancer	0.00026	0.000997	CcSEcCtD
Raloxifene—Connective tissue disorder—Docetaxel—lung cancer	0.00026	0.000995	CcSEcCtD
Raloxifene—Nervous system disorder—Gemcitabine—lung cancer	0.000259	0.000994	CcSEcCtD
Raloxifene—Urethral disorder—Docetaxel—lung cancer	0.000259	0.000992	CcSEcCtD
Raloxifene—Thrombocytopenia—Gemcitabine—lung cancer	0.000259	0.000992	CcSEcCtD
Raloxifene—Myalgia—Cisplatin—lung cancer	0.000257	0.000985	CcSEcCtD
Raloxifene—Skin disorder—Gemcitabine—lung cancer	0.000257	0.000984	CcSEcCtD
Raloxifene—Hyperhidrosis—Gemcitabine—lung cancer	0.000256	0.00098	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—lung cancer	0.000256	0.000978	CcSEcCtD
Raloxifene—Hot flush—Doxorubicin—lung cancer	0.000255	0.000976	CcSEcCtD
Raloxifene—Dizziness—Topotecan—lung cancer	0.000255	0.000975	CcSEcCtD
Raloxifene—Menopausal symptoms—Doxorubicin—lung cancer	0.000253	0.000968	CcSEcCtD
Raloxifene—Vomiting—Vinblastine—lung cancer	0.000252	0.000965	CcSEcCtD
Raloxifene—Dizziness—Erlotinib—lung cancer	0.000252	0.000965	CcSEcCtD
Raloxifene—Breast disorder—Methotrexate—lung cancer	0.000249	0.000953	CcSEcCtD
Raloxifene—Vertigo—Etoposide—lung cancer	0.000249	0.000952	CcSEcCtD
Raloxifene—Headache—Vinblastine—lung cancer	0.000248	0.000951	CcSEcCtD
Raloxifene—Insomnia—Irinotecan—lung cancer	0.000246	0.000941	CcSEcCtD
Raloxifene—Cardiac disorder—Docetaxel—lung cancer	0.000245	0.000939	CcSEcCtD
Raloxifene—Flushing—Docetaxel—lung cancer	0.000245	0.000939	CcSEcCtD
Raloxifene—Infection—Cisplatin—lung cancer	0.000245	0.000938	CcSEcCtD
Raloxifene—Vomiting—Topotecan—lung cancer	0.000245	0.000937	CcSEcCtD
Raloxifene—Vertigo—Paclitaxel—lung cancer	0.000244	0.000934	CcSEcCtD
Raloxifene—Syncope—Paclitaxel—lung cancer	0.000243	0.000932	CcSEcCtD
Raloxifene—Loss of consciousness—Etoposide—lung cancer	0.000243	0.000932	CcSEcCtD
Raloxifene—Cerebrovascular accident—Doxorubicin—lung cancer	0.000243	0.000932	CcSEcCtD
Raloxifene—Rash—Topotecan—lung cancer	0.000243	0.00093	CcSEcCtD
Raloxifene—Dermatitis—Topotecan—lung cancer	0.000243	0.000929	CcSEcCtD
Raloxifene—Vomiting—Erlotinib—lung cancer	0.000242	0.000928	CcSEcCtD
Raloxifene—Nervous system disorder—Cisplatin—lung cancer	0.000242	0.000926	CcSEcCtD
Raloxifene—Cough—Etoposide—lung cancer	0.000242	0.000925	CcSEcCtD
Raloxifene—Thrombocytopenia—Cisplatin—lung cancer	0.000241	0.000925	CcSEcCtD
Raloxifene—Headache—Topotecan—lung cancer	0.000241	0.000924	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Gemcitabine—lung cancer	0.000241	0.000923	CcSEcCtD
Raloxifene—Rash—Erlotinib—lung cancer	0.00024	0.00092	CcSEcCtD
Raloxifene—Dermatitis—Erlotinib—lung cancer	0.00024	0.000919	CcSEcCtD
Raloxifene—Angiopathy—Docetaxel—lung cancer	0.00024	0.000918	CcSEcCtD
Raloxifene—Skin disorder—Cisplatin—lung cancer	0.00024	0.000917	CcSEcCtD
Raloxifene—Insomnia—Gemcitabine—lung cancer	0.000239	0.000916	CcSEcCtD
Raloxifene—Dyspepsia—Irinotecan—lung cancer	0.000239	0.000916	CcSEcCtD
Raloxifene—Headache—Erlotinib—lung cancer	0.000239	0.000914	CcSEcCtD
Raloxifene—Loss of consciousness—Paclitaxel—lung cancer	0.000239	0.000914	CcSEcCtD
Raloxifene—Hyperhidrosis—Cisplatin—lung cancer	0.000238	0.000913	CcSEcCtD
Raloxifene—Cough—Paclitaxel—lung cancer	0.000237	0.000907	CcSEcCtD
Raloxifene—Chest pain—Etoposide—lung cancer	0.000236	0.000903	CcSEcCtD
Raloxifene—Nausea—Vinblastine—lung cancer	0.000235	0.000902	CcSEcCtD
Raloxifene—Migraine—Doxorubicin—lung cancer	0.000235	0.000899	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Irinotecan—lung cancer	0.000235	0.000898	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Etoposide—lung cancer	0.000234	0.000896	CcSEcCtD
Raloxifene—Pain—Irinotecan—lung cancer	0.000232	0.00089	CcSEcCtD
Raloxifene—Myalgia—Paclitaxel—lung cancer	0.000231	0.000885	CcSEcCtD
Raloxifene—Arthralgia—Paclitaxel—lung cancer	0.000231	0.000885	CcSEcCtD
Raloxifene—Chest pain—Paclitaxel—lung cancer	0.000231	0.000885	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—lung cancer	0.00023	0.000879	CcSEcCtD
Raloxifene—Nausea—Topotecan—lung cancer	0.000229	0.000876	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Gemcitabine—lung cancer	0.000228	0.000875	CcSEcCtD
Raloxifene—Pain—Gemcitabine—lung cancer	0.000226	0.000866	CcSEcCtD
Raloxifene—Nausea—Erlotinib—lung cancer	0.000226	0.000866	CcSEcCtD
Raloxifene—Diarrhoea—Vinorelbine—lung cancer	0.000225	0.000863	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Cisplatin—lung cancer	0.000225	0.00086	CcSEcCtD
Raloxifene—Infection—Etoposide—lung cancer	0.000224	0.00086	CcSEcCtD
Raloxifene—Gastrointestinal pain—Irinotecan—lung cancer	0.000222	0.000851	CcSEcCtD
Raloxifene—Thrombocytopenia—Etoposide—lung cancer	0.000221	0.000847	CcSEcCtD
Raloxifene—Muscle spasms—Docetaxel—lung cancer	0.000221	0.000847	CcSEcCtD
Raloxifene—Infection—Paclitaxel—lung cancer	0.00022	0.000843	CcSEcCtD
Raloxifene—Skin disorder—Etoposide—lung cancer	0.000219	0.00084	CcSEcCtD
Raloxifene—Hyperhidrosis—Etoposide—lung cancer	0.000218	0.000836	CcSEcCtD
Raloxifene—Shock—Paclitaxel—lung cancer	0.000218	0.000835	CcSEcCtD
Raloxifene—Dizziness—Vinorelbine—lung cancer	0.000218	0.000834	CcSEcCtD
Raloxifene—Nervous system disorder—Paclitaxel—lung cancer	0.000217	0.000832	CcSEcCtD
Raloxifene—Thrombocytopenia—Paclitaxel—lung cancer	0.000217	0.000831	CcSEcCtD
Raloxifene—Breast disorder—Doxorubicin—lung cancer	0.000215	0.000825	CcSEcCtD
Raloxifene—Skin disorder—Paclitaxel—lung cancer	0.000215	0.000824	CcSEcCtD
Raloxifene—Abdominal pain—Irinotecan—lung cancer	0.000215	0.000822	CcSEcCtD
Raloxifene—Body temperature increased—Irinotecan—lung cancer	0.000215	0.000822	CcSEcCtD
Raloxifene—Aspartate aminotransferase increased—Doxorubicin—lung cancer	0.000215	0.000822	CcSEcCtD
Raloxifene—Hyperhidrosis—Paclitaxel—lung cancer	0.000214	0.00082	CcSEcCtD
Raloxifene—Pneumonia—Methotrexate—lung cancer	0.000213	0.000817	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Cisplatin—lung cancer	0.000213	0.000815	CcSEcCtD
Raloxifene—Depression—Methotrexate—lung cancer	0.000212	0.00081	CcSEcCtD
Raloxifene—Pain—Cisplatin—lung cancer	0.000211	0.000808	CcSEcCtD
Raloxifene—Vomiting—Vinorelbine—lung cancer	0.000209	0.000802	CcSEcCtD
Raloxifene—Body temperature increased—Gemcitabine—lung cancer	0.000209	0.000801	CcSEcCtD
Raloxifene—Rash—Vinorelbine—lung cancer	0.000208	0.000795	CcSEcCtD
Raloxifene—Dermatitis—Vinorelbine—lung cancer	0.000207	0.000795	CcSEcCtD
Raloxifene—Headache—Vinorelbine—lung cancer	0.000206	0.00079	CcSEcCtD
Raloxifene—Syncope—Docetaxel—lung cancer	0.000206	0.00079	CcSEcCtD
Raloxifene—Conjunctivitis—Methotrexate—lung cancer	0.000206	0.00079	CcSEcCtD
Raloxifene—Influenza—Doxorubicin—lung cancer	0.000206	0.000789	CcSEcCtD
Raloxifene—Sweating—Methotrexate—lung cancer	0.000203	0.000779	CcSEcCtD
Raloxifene—Loss of consciousness—Docetaxel—lung cancer	0.000202	0.000774	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Paclitaxel—lung cancer	0.000202	0.000773	CcSEcCtD
Raloxifene—Cough—Docetaxel—lung cancer	0.000201	0.000769	CcSEcCtD
Raloxifene—Insomnia—Paclitaxel—lung cancer	0.0002	0.000767	CcSEcCtD
Raloxifene—Bronchitis—Doxorubicin—lung cancer	0.000198	0.000759	CcSEcCtD
Raloxifene—Chest pain—Docetaxel—lung cancer	0.000196	0.00075	CcSEcCtD
Raloxifene—Arthralgia—Docetaxel—lung cancer	0.000196	0.00075	CcSEcCtD
Raloxifene—Myalgia—Docetaxel—lung cancer	0.000196	0.00075	CcSEcCtD
Raloxifene—Nausea—Vinorelbine—lung cancer	0.000196	0.000749	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Etoposide—lung cancer	0.000195	0.000747	CcSEcCtD
Raloxifene—Dyspepsia—Paclitaxel—lung cancer	0.000195	0.000747	CcSEcCtD
Raloxifene—Body temperature increased—Cisplatin—lung cancer	0.000195	0.000747	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	0.000195	0.000745	CcSEcCtD
Raloxifene—Pain—Etoposide—lung cancer	0.000193	0.00074	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Paclitaxel—lung cancer	0.000191	0.000732	CcSEcCtD
Raloxifene—Pain—Paclitaxel—lung cancer	0.000189	0.000725	CcSEcCtD
Raloxifene—Pharyngitis—Methotrexate—lung cancer	0.000189	0.000724	CcSEcCtD
Raloxifene—Urinary tract disorder—Methotrexate—lung cancer	0.000188	0.00072	CcSEcCtD
Raloxifene—Weight increased—Doxorubicin—lung cancer	0.000188	0.000718	CcSEcCtD
Raloxifene—Urethral disorder—Methotrexate—lung cancer	0.000187	0.000715	CcSEcCtD
Raloxifene—Infection—Docetaxel—lung cancer	0.000187	0.000714	CcSEcCtD
Raloxifene—Diarrhoea—Irinotecan—lung cancer	0.000186	0.000712	CcSEcCtD
Raloxifene—Pneumonia—Doxorubicin—lung cancer	0.000185	0.000708	CcSEcCtD
Raloxifene—Gastrointestinal pain—Etoposide—lung cancer	0.000185	0.000708	CcSEcCtD
Raloxifene—Shock—Docetaxel—lung cancer	0.000185	0.000707	CcSEcCtD
Raloxifene—Nervous system disorder—Docetaxel—lung cancer	0.000184	0.000705	CcSEcCtD
Raloxifene—Thrombocytopenia—Docetaxel—lung cancer	0.000184	0.000704	CcSEcCtD
Raloxifene—Skin disorder—Docetaxel—lung cancer	0.000182	0.000698	CcSEcCtD
Raloxifene—Gastrointestinal pain—Paclitaxel—lung cancer	0.000181	0.000694	CcSEcCtD
Raloxifene—Diarrhoea—Gemcitabine—lung cancer	0.000181	0.000693	CcSEcCtD
Raloxifene—Dizziness—Irinotecan—lung cancer	0.00018	0.000688	CcSEcCtD
Raloxifene—Body temperature increased—Etoposide—lung cancer	0.000179	0.000684	CcSEcCtD
Raloxifene—Abdominal pain—Etoposide—lung cancer	0.000179	0.000684	CcSEcCtD
Raloxifene—Urinary tract infection—Doxorubicin—lung cancer	0.000179	0.000684	CcSEcCtD
Raloxifene—Conjunctivitis—Doxorubicin—lung cancer	0.000179	0.000684	CcSEcCtD
Raloxifene—Cardiac disorder—Methotrexate—lung cancer	0.000177	0.000677	CcSEcCtD
Raloxifene—Sweating—Doxorubicin—lung cancer	0.000176	0.000675	CcSEcCtD
Raloxifene—Body temperature increased—Paclitaxel—lung cancer	0.000175	0.000671	CcSEcCtD
Raloxifene—Abdominal pain—Paclitaxel—lung cancer	0.000175	0.000671	CcSEcCtD
Raloxifene—Angiopathy—Methotrexate—lung cancer	0.000173	0.000662	CcSEcCtD
Raloxifene—Vomiting—Irinotecan—lung cancer	0.000173	0.000661	CcSEcCtD
Raloxifene—Sinusitis—Doxorubicin—lung cancer	0.000172	0.00066	CcSEcCtD
Raloxifene—Rash—Irinotecan—lung cancer	0.000171	0.000656	CcSEcCtD
Raloxifene—Dermatitis—Irinotecan—lung cancer	0.000171	0.000655	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Docetaxel—lung cancer	0.000171	0.000655	CcSEcCtD
Raloxifene—Headache—Irinotecan—lung cancer	0.00017	0.000652	CcSEcCtD
Raloxifene—Insomnia—Docetaxel—lung cancer	0.00017	0.00065	CcSEcCtD
Raloxifene—Diarrhoea—Cisplatin—lung cancer	0.000169	0.000646	CcSEcCtD
Raloxifene—Vomiting—Gemcitabine—lung cancer	0.000168	0.000644	CcSEcCtD
Raloxifene—Rash—Gemcitabine—lung cancer	0.000167	0.000639	CcSEcCtD
Raloxifene—Dermatitis—Gemcitabine—lung cancer	0.000167	0.000638	CcSEcCtD
Raloxifene—Headache—Gemcitabine—lung cancer	0.000166	0.000635	CcSEcCtD
Raloxifene—Rhinitis—Doxorubicin—lung cancer	0.000165	0.000633	CcSEcCtD
Raloxifene—Dyspepsia—Docetaxel—lung cancer	0.000165	0.000633	CcSEcCtD
Raloxifene—Hypoaesthesia—Doxorubicin—lung cancer	0.000164	0.000628	CcSEcCtD
Raloxifene—Pharyngitis—Doxorubicin—lung cancer	0.000164	0.000627	CcSEcCtD
Raloxifene—Urinary tract disorder—Doxorubicin—lung cancer	0.000163	0.000624	CcSEcCtD
Raloxifene—Oedema peripheral—Doxorubicin—lung cancer	0.000162	0.000622	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Docetaxel—lung cancer	0.000162	0.000621	CcSEcCtD
Raloxifene—Connective tissue disorder—Doxorubicin—lung cancer	0.000162	0.000621	CcSEcCtD
Raloxifene—Urethral disorder—Doxorubicin—lung cancer	0.000162	0.000619	CcSEcCtD
Raloxifene—Nausea—Irinotecan—lung cancer	0.000161	0.000618	CcSEcCtD
Raloxifene—Pain—Docetaxel—lung cancer	0.000161	0.000615	CcSEcCtD
Raloxifene—Nausea—Gemcitabine—lung cancer	0.000157	0.000602	CcSEcCtD
Raloxifene—Vomiting—Cisplatin—lung cancer	0.000157	0.0006	CcSEcCtD
Raloxifene—Rash—Cisplatin—lung cancer	0.000156	0.000595	CcSEcCtD
Raloxifene—Dermatitis—Cisplatin—lung cancer	0.000155	0.000595	CcSEcCtD
Raloxifene—Diarrhoea—Etoposide—lung cancer	0.000155	0.000592	CcSEcCtD
Raloxifene—Gastrointestinal pain—Docetaxel—lung cancer	0.000154	0.000588	CcSEcCtD
Raloxifene—Flushing—Doxorubicin—lung cancer	0.000153	0.000586	CcSEcCtD
Raloxifene—Cardiac disorder—Doxorubicin—lung cancer	0.000153	0.000586	CcSEcCtD
Raloxifene—Diarrhoea—Paclitaxel—lung cancer	0.000152	0.00058	CcSEcCtD
Raloxifene—Angiopathy—Doxorubicin—lung cancer	0.00015	0.000573	CcSEcCtD
Raloxifene—Dizziness—Etoposide—lung cancer	0.000149	0.000572	CcSEcCtD
Raloxifene—Vertigo—Methotrexate—lung cancer	0.000149	0.000571	CcSEcCtD
Raloxifene—Abdominal pain—Docetaxel—lung cancer	0.000148	0.000568	CcSEcCtD
Raloxifene—Body temperature increased—Docetaxel—lung cancer	0.000148	0.000568	CcSEcCtD
Raloxifene—Dizziness—Paclitaxel—lung cancer	0.000146	0.000561	CcSEcCtD
Raloxifene—Nausea—Cisplatin—lung cancer	0.000146	0.000561	CcSEcCtD
Raloxifene—Cough—Methotrexate—lung cancer	0.000145	0.000554	CcSEcCtD
Raloxifene—Vomiting—Etoposide—lung cancer	0.000144	0.00055	CcSEcCtD
Raloxifene—Rash—Etoposide—lung cancer	0.000142	0.000546	CcSEcCtD
Raloxifene—Dermatitis—Etoposide—lung cancer	0.000142	0.000545	CcSEcCtD
Raloxifene—Headache—Etoposide—lung cancer	0.000142	0.000542	CcSEcCtD
Raloxifene—Flatulence—Doxorubicin—lung cancer	0.000141	0.000542	CcSEcCtD
Raloxifene—Chest pain—Methotrexate—lung cancer	0.000141	0.000541	CcSEcCtD
Raloxifene—Arthralgia—Methotrexate—lung cancer	0.000141	0.000541	CcSEcCtD
Raloxifene—Myalgia—Methotrexate—lung cancer	0.000141	0.000541	CcSEcCtD
Raloxifene—Vomiting—Paclitaxel—lung cancer	0.000141	0.000539	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	0.00014	0.000537	CcSEcCtD
Raloxifene—Rash—Paclitaxel—lung cancer	0.00014	0.000535	CcSEcCtD
Raloxifene—Dermatitis—Paclitaxel—lung cancer	0.00014	0.000534	CcSEcCtD
Raloxifene—Headache—Paclitaxel—lung cancer	0.000139	0.000531	CcSEcCtD
Raloxifene—Muscle spasms—Doxorubicin—lung cancer	0.000138	0.000529	CcSEcCtD
Raloxifene—Infection—Methotrexate—lung cancer	0.000134	0.000515	CcSEcCtD
Raloxifene—Nausea—Etoposide—lung cancer	0.000134	0.000514	CcSEcCtD
Raloxifene—Nervous system disorder—Methotrexate—lung cancer	0.000133	0.000508	CcSEcCtD
Raloxifene—Thrombocytopenia—Methotrexate—lung cancer	0.000133	0.000507	CcSEcCtD
Raloxifene—Nausea—Paclitaxel—lung cancer	0.000132	0.000504	CcSEcCtD
Raloxifene—Skin disorder—Methotrexate—lung cancer	0.000131	0.000503	CcSEcCtD
Raloxifene—Hyperhidrosis—Methotrexate—lung cancer	0.000131	0.000501	CcSEcCtD
Raloxifene—Vertigo—Doxorubicin—lung cancer	0.000129	0.000494	CcSEcCtD
Raloxifene—Syncope—Doxorubicin—lung cancer	0.000129	0.000493	CcSEcCtD
Raloxifene—Diarrhoea—Docetaxel—lung cancer	0.000128	0.000492	CcSEcCtD
Raloxifene—Loss of consciousness—Doxorubicin—lung cancer	0.000126	0.000483	CcSEcCtD
Raloxifene—Cough—Doxorubicin—lung cancer	0.000125	0.00048	CcSEcCtD
Raloxifene—Dizziness—Docetaxel—lung cancer	0.000124	0.000476	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Methotrexate—lung cancer	0.000123	0.000472	CcSEcCtD
Raloxifene—Insomnia—Methotrexate—lung cancer	0.000122	0.000469	CcSEcCtD
Raloxifene—Chest pain—Doxorubicin—lung cancer	0.000122	0.000468	CcSEcCtD
Raloxifene—Arthralgia—Doxorubicin—lung cancer	0.000122	0.000468	CcSEcCtD
Raloxifene—Myalgia—Doxorubicin—lung cancer	0.000122	0.000468	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	0.000121	0.000465	CcSEcCtD
Raloxifene—Vomiting—Docetaxel—lung cancer	0.000119	0.000457	CcSEcCtD
Raloxifene—Dyspepsia—Methotrexate—lung cancer	0.000119	0.000456	CcSEcCtD
Raloxifene—Rash—Docetaxel—lung cancer	0.000118	0.000453	CcSEcCtD
Raloxifene—Dermatitis—Docetaxel—lung cancer	0.000118	0.000453	CcSEcCtD
Raloxifene—Headache—Docetaxel—lung cancer	0.000118	0.00045	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Methotrexate—lung cancer	0.000117	0.000447	CcSEcCtD
Raloxifene—Infection—Doxorubicin—lung cancer	0.000116	0.000446	CcSEcCtD
Raloxifene—Pain—Methotrexate—lung cancer	0.000116	0.000443	CcSEcCtD
Raloxifene—Shock—Doxorubicin—lung cancer	0.000115	0.000442	CcSEcCtD
Raloxifene—Nervous system disorder—Doxorubicin—lung cancer	0.000115	0.00044	CcSEcCtD
Raloxifene—Thrombocytopenia—Doxorubicin—lung cancer	0.000115	0.000439	CcSEcCtD
Raloxifene—Skin disorder—Doxorubicin—lung cancer	0.000114	0.000436	CcSEcCtD
Raloxifene—Hyperhidrosis—Doxorubicin—lung cancer	0.000113	0.000434	CcSEcCtD
Raloxifene—Nausea—Docetaxel—lung cancer	0.000112	0.000427	CcSEcCtD
Raloxifene—Gastrointestinal pain—Methotrexate—lung cancer	0.000111	0.000424	CcSEcCtD
Raloxifene—Body temperature increased—Methotrexate—lung cancer	0.000107	0.00041	CcSEcCtD
Raloxifene—Abdominal pain—Methotrexate—lung cancer	0.000107	0.00041	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Doxorubicin—lung cancer	0.000107	0.000409	CcSEcCtD
Raloxifene—Insomnia—Doxorubicin—lung cancer	0.000106	0.000406	CcSEcCtD
Raloxifene—Dyspepsia—Doxorubicin—lung cancer	0.000103	0.000395	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Doxorubicin—lung cancer	0.000101	0.000387	CcSEcCtD
Raloxifene—Pain—Doxorubicin—lung cancer	0.0001	0.000384	CcSEcCtD
Raloxifene—Gastrointestinal pain—Doxorubicin—lung cancer	9.58e-05	0.000367	CcSEcCtD
Raloxifene—Body temperature increased—Doxorubicin—lung cancer	9.26e-05	0.000355	CcSEcCtD
Raloxifene—Abdominal pain—Doxorubicin—lung cancer	9.26e-05	0.000355	CcSEcCtD
Raloxifene—Diarrhoea—Methotrexate—lung cancer	9.26e-05	0.000355	CcSEcCtD
Raloxifene—Dizziness—Methotrexate—lung cancer	8.95e-05	0.000343	CcSEcCtD
Raloxifene—Vomiting—Methotrexate—lung cancer	8.61e-05	0.00033	CcSEcCtD
Raloxifene—Rash—Methotrexate—lung cancer	8.53e-05	0.000327	CcSEcCtD
Raloxifene—Dermatitis—Methotrexate—lung cancer	8.53e-05	0.000326	CcSEcCtD
Raloxifene—Headache—Methotrexate—lung cancer	8.48e-05	0.000325	CcSEcCtD
Raloxifene—Nausea—Methotrexate—lung cancer	8.04e-05	0.000308	CcSEcCtD
Raloxifene—Diarrhoea—Doxorubicin—lung cancer	8.02e-05	0.000307	CcSEcCtD
Raloxifene—Dizziness—Doxorubicin—lung cancer	7.75e-05	0.000297	CcSEcCtD
Raloxifene—Vomiting—Doxorubicin—lung cancer	7.45e-05	0.000285	CcSEcCtD
Raloxifene—Rash—Doxorubicin—lung cancer	7.39e-05	0.000283	CcSEcCtD
Raloxifene—Dermatitis—Doxorubicin—lung cancer	7.38e-05	0.000283	CcSEcCtD
Raloxifene—Headache—Doxorubicin—lung cancer	7.34e-05	0.000281	CcSEcCtD
Raloxifene—Nausea—Doxorubicin—lung cancer	6.96e-05	0.000267	CcSEcCtD
Raloxifene—CYP2B6—Metabolism—STK11—lung cancer	1.33e-05	7.98e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—HES1—lung cancer	1.32e-05	7.95e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PIK3CG—lung cancer	1.3e-05	7.84e-05	CbGpPWpGaD
Raloxifene—AOX1—Disease—HRAS—lung cancer	1.3e-05	7.83e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—APC—lung cancer	1.28e-05	7.72e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—KIT—lung cancer	1.28e-05	7.72e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PIK3CG—lung cancer	1.28e-05	7.72e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—NRAS—lung cancer	1.28e-05	7.72e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—APOA1—lung cancer	1.28e-05	7.72e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—KDR—lung cancer	1.27e-05	7.65e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—EGF—lung cancer	1.27e-05	7.63e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—CYP2E1—lung cancer	1.26e-05	7.58e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—NQO1—lung cancer	1.25e-05	7.49e-05	CbGpPWpGaD
Raloxifene—AOX1—Disease—IL6—lung cancer	1.25e-05	7.49e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—POMC—lung cancer	1.24e-05	7.47e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—MAPK3—lung cancer	1.23e-05	7.39e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—GSTP1—lung cancer	1.23e-05	7.38e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—POMC—lung cancer	1.22e-05	7.35e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—RRM1—lung cancer	1.22e-05	7.34e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GSTA3—lung cancer	1.22e-05	7.34e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	1.22e-05	7.34e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—CREBBP—lung cancer	1.21e-05	7.27e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—ERBB3—lung cancer	1.21e-05	7.27e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	1.21e-05	7.27e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—BRAF—lung cancer	1.21e-05	7.26e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—CAT—lung cancer	1.19e-05	7.18e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—IL6R—lung cancer	1.19e-05	7.17e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CREBBP—lung cancer	1.19e-05	7.16e-05	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—PIK3CA—lung cancer	1.18e-05	7.08e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—APC—lung cancer	1.17e-05	7.05e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PIK3CG—lung cancer	1.17e-05	7.05e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—KIT—lung cancer	1.17e-05	7.05e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—NRAS—lung cancer	1.17e-05	7.05e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—EGFR—lung cancer	1.17e-05	7.03e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—ABCB1—lung cancer	1.16e-05	6.99e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—TERT—lung cancer	1.16e-05	6.97e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—EGF—lung cancer	1.16e-05	6.97e-05	CbGpPWpGaD
Raloxifene—AOX1—Disease—AKT1—lung cancer	1.15e-05	6.91e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—B4GALT5—lung cancer	1.15e-05	6.9e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PIK3CD—lung cancer	1.15e-05	6.9e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—TYMS—lung cancer	1.14e-05	6.86e-05	CbGpPWpGaD
Raloxifene—ESR2—Gene Expression—AKT1—lung cancer	1.14e-05	6.83e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—MAP2K1—lung cancer	1.14e-05	6.83e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—ALB—lung cancer	1.13e-05	6.81e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PIK3CD—lung cancer	1.13e-05	6.79e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—GSTM1—lung cancer	1.13e-05	6.78e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—FGFR1—lung cancer	1.13e-05	6.77e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—STK11—lung cancer	1.12e-05	6.75e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—MAPK3—lung cancer	1.12e-05	6.75e-05	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—PIK3CA—lung cancer	1.12e-05	6.72e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GSTA4—lung cancer	1.12e-05	6.71e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—POMC—lung cancer	1.12e-05	6.71e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—HIF1A—lung cancer	1.11e-05	6.66e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—KRAS—lung cancer	1.11e-05	6.65e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—BRAF—lung cancer	1.1e-05	6.63e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—IL6R—lung cancer	1.09e-05	6.54e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GSTA2—lung cancer	1.09e-05	6.54e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CREBBP—lung cancer	1.09e-05	6.53e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—APOA1—lung cancer	1.07e-05	6.43e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—CYP1A1—lung cancer	1.07e-05	6.43e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—EGFR—lung cancer	1.07e-05	6.42e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—ERCC2—lung cancer	1.06e-05	6.38e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—KDR—lung cancer	1.06e-05	6.37e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—lung cancer	1.05e-05	6.34e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GSTA1—lung cancer	1.05e-05	6.31e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—GSTP1—lung cancer	1.04e-05	6.25e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ABCC3—lung cancer	1.04e-05	6.24e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—MAP2K1—lung cancer	1.04e-05	6.24e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PIK3CD—lung cancer	1.03e-05	6.2e-05	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—PIK3CA—lung cancer	1.02e-05	6.14e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—PIK3CA—lung cancer	1.02e-05	6.11e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—CAT—lung cancer	1.01e-05	6.08e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—MDM2—lung cancer	1.01e-05	6.08e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—KRAS—lung cancer	1.01e-05	6.07e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—RAF1—lung cancer	1.01e-05	6.06e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—EP300—lung cancer	1.01e-05	6.05e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—AKR1C1—lung cancer	1.01e-05	6.04e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PIK3CB—lung cancer	9.99e-06	6.01e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—ERBB2—lung cancer	9.97e-06	6e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PTGS2—lung cancer	9.9e-06	5.95e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PIK3CB—lung cancer	9.84e-06	5.92e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—MTOR—lung cancer	9.84e-06	5.92e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—ABCB1—lung cancer	9.84e-06	5.92e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—APC—lung cancer	9.76e-06	5.87e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—KIT—lung cancer	9.76e-06	5.87e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PIK3CG—lung cancer	9.76e-06	5.87e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—UGT1A1—lung cancer	9.76e-06	5.87e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—TYMS—lung cancer	9.66e-06	5.81e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—EGF—lung cancer	9.65e-06	5.8e-05	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—AKT1—lung cancer	9.62e-06	5.79e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—GSTM1—lung cancer	9.55e-06	5.74e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CXCL8—lung cancer	9.45e-06	5.69e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GNG11—lung cancer	9.41e-06	5.66e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—HRAS—lung cancer	9.39e-06	5.65e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—POMC—lung cancer	9.29e-06	5.59e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—PIK3CA—lung cancer	9.27e-06	5.57e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—MDM2—lung cancer	9.23e-06	5.55e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—RAF1—lung cancer	9.2e-06	5.53e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—BRAF—lung cancer	9.18e-06	5.52e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—APOA1—lung cancer	9.17e-06	5.52e-05	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—AKT1—lung cancer	9.13e-06	5.49e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—ERBB2—lung cancer	9.1e-06	5.47e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—IL6R—lung cancer	9.07e-06	5.45e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—CYP1A1—lung cancer	9.05e-06	5.44e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CREBBP—lung cancer	9.05e-06	5.44e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CASP3—lung cancer	9.05e-06	5.44e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—IL2—lung cancer	9.03e-06	5.43e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—IL6—lung cancer	8.99e-06	5.41e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—MTOR—lung cancer	8.98e-06	5.4e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PIK3CB—lung cancer	8.98e-06	5.4e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—ERCC2—lung cancer	8.98e-06	5.4e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ALDOA—lung cancer	8.96e-06	5.39e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CCND1—lung cancer	8.81e-06	5.3e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—JUN—lung cancer	8.79e-06	5.29e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—NCOA3—lung cancer	8.7e-06	5.23e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MAP2K1—lung cancer	8.64e-06	5.2e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PTEN—lung cancer	8.64e-06	5.19e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CXCL8—lung cancer	8.63e-06	5.19e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PIK3CD—lung cancer	8.58e-06	5.16e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—HRAS—lung cancer	8.57e-06	5.16e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—MMP9—lung cancer	8.55e-06	5.14e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CDKN1A—lung cancer	8.52e-06	5.12e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PTEN—lung cancer	8.5e-06	5.11e-05	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—MAPK3—lung cancer	8.49e-06	5.11e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ADCY1—lung cancer	8.46e-06	5.09e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ABCG2—lung cancer	8.46e-06	5.09e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PIK3CG—lung cancer	8.38e-06	5.04e-05	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—AKT1—lung cancer	8.34e-06	5.01e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ENO2—lung cancer	8.3e-06	4.99e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—HPGDS—lung cancer	8.3e-06	4.99e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—AKT1—lung cancer	8.29e-06	4.99e-05	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—MYC—lung cancer	8.26e-06	4.97e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CASP3—lung cancer	8.26e-06	4.97e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—IL2—lung cancer	8.25e-06	4.96e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PPP2R1B—lung cancer	8.24e-06	4.96e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—EP300—lung cancer	8.24e-06	4.95e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—IL6—lung cancer	8.21e-06	4.94e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—EP300—lung cancer	8.11e-06	4.88e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GSTT1—lung cancer	8.05e-06	4.84e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CCND1—lung cancer	8.04e-06	4.84e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—JUN—lung cancer	8.02e-06	4.82e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—POMC—lung cancer	7.97e-06	4.79e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GCLC—lung cancer	7.95e-06	4.78e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CYP2A6—lung cancer	7.95e-06	4.78e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—SRC—lung cancer	7.88e-06	4.74e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—MMP9—lung cancer	7.81e-06	4.69e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CDKN1A—lung cancer	7.78e-06	4.68e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—APOA1—lung cancer	7.77e-06	4.67e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—CREBBP—lung cancer	7.77e-06	4.67e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PTEN—lung cancer	7.76e-06	4.67e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MDM2—lung cancer	7.69e-06	4.62e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—VEGFA—lung cancer	7.68e-06	4.62e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—RAF1—lung cancer	7.66e-06	4.61e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—STAT3—lung cancer	7.6e-06	4.57e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—NRAS—lung cancer	7.58e-06	4.56e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—ERBB2—lung cancer	7.58e-06	4.56e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—AKT1—lung cancer	7.57e-06	4.55e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ENO1—lung cancer	7.54e-06	4.53e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PIK3CB—lung cancer	7.48e-06	4.5e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MTOR—lung cancer	7.48e-06	4.5e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	7.44e-06	4.47e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—EP300—lung cancer	7.4e-06	4.45e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PIK3CD—lung cancer	7.36e-06	4.43e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—ALB—lung cancer	7.27e-06	4.37e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—MAPK3—lung cancer	7.26e-06	4.37e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—SRC—lung cancer	7.2e-06	4.33e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CXCL8—lung cancer	7.19e-06	4.32e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PIK3CG—lung cancer	7.09e-06	4.26e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—MYC—lung cancer	7.06e-06	4.25e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—VEGFA—lung cancer	7.01e-06	4.22e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—STAT3—lung cancer	6.94e-06	4.17e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—NRAS—lung cancer	6.92e-06	4.16e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—EGFR—lung cancer	6.91e-06	4.16e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CASP3—lung cancer	6.88e-06	4.14e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—IL2—lung cancer	6.87e-06	4.13e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CYP2E1—lung cancer	6.76e-06	4.07e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—POMC—lung cancer	6.75e-06	4.06e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CCND1—lung cancer	6.7e-06	4.03e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—NQO1—lung cancer	6.69e-06	4.02e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—JUN—lung cancer	6.68e-06	4.02e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—MAPK3—lung cancer	6.63e-06	3.99e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—CREBBP—lung cancer	6.57e-06	3.95e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—KRAS—lung cancer	6.53e-06	3.93e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MMP9—lung cancer	6.5e-06	3.91e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CDKN1A—lung cancer	6.48e-06	3.9e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PTEN—lung cancer	6.46e-06	3.89e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—MYC—lung cancer	6.45e-06	3.88e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PIK3CB—lung cancer	6.42e-06	3.86e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PTGS2—lung cancer	6.36e-06	3.82e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—EGFR—lung cancer	6.31e-06	3.79e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PIK3CD—lung cancer	6.23e-06	3.75e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—EP300—lung cancer	6.16e-06	3.71e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—ALB—lung cancer	6.15e-06	3.7e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PIK3CA—lung cancer	6.09e-06	3.66e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—STK11—lung cancer	6.03e-06	3.63e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PIK3CA—lung cancer	6e-06	3.61e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—SRC—lung cancer	5.99e-06	3.61e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—KRAS—lung cancer	5.96e-06	3.58e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—VEGFA—lung cancer	5.84e-06	3.51e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—TP53—lung cancer	5.8e-06	3.49e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—STAT3—lung cancer	5.78e-06	3.48e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—NRAS—lung cancer	5.77e-06	3.47e-05	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—AKT1—lung cancer	5.73e-06	3.45e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GSTP1—lung cancer	5.58e-06	3.35e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—HRAS—lung cancer	5.55e-06	3.34e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PTEN—lung cancer	5.55e-06	3.34e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MAPK3—lung cancer	5.52e-06	3.32e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PIK3CA—lung cancer	5.47e-06	3.29e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PIK3CB—lung cancer	5.43e-06	3.27e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CAT—lung cancer	5.43e-06	3.26e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PTGS2—lung cancer	5.38e-06	3.24e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MYC—lung cancer	5.37e-06	3.23e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—IL6—lung cancer	5.31e-06	3.19e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—TP53—lung cancer	5.3e-06	3.19e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—EP300—lung cancer	5.29e-06	3.18e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ABCB1—lung cancer	5.28e-06	3.18e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—EGFR—lung cancer	5.25e-06	3.16e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—TYMS—lung cancer	5.19e-06	3.12e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GSTM1—lung cancer	5.13e-06	3.08e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—HRAS—lung cancer	5.06e-06	3.05e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—AKT1—lung cancer	4.98e-06	2.99e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—KRAS—lung cancer	4.96e-06	2.99e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—AKT1—lung cancer	4.9e-06	2.95e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CYP1A1—lung cancer	4.86e-06	2.92e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—IL6—lung cancer	4.85e-06	2.92e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ERCC2—lung cancer	4.82e-06	2.9e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PTEN—lung cancer	4.69e-06	2.82e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PIK3CA—lung cancer	4.56e-06	2.74e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—EP300—lung cancer	4.48e-06	2.69e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—AKT1—lung cancer	4.47e-06	2.69e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—TP53—lung cancer	4.41e-06	2.65e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—HRAS—lung cancer	4.22e-06	2.54e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—APOA1—lung cancer	4.17e-06	2.51e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—IL6—lung cancer	4.04e-06	2.43e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PIK3CA—lung cancer	3.91e-06	2.35e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PIK3CG—lung cancer	3.81e-06	2.29e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—AKT1—lung cancer	3.73e-06	2.24e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—POMC—lung cancer	3.62e-06	2.18e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CREBBP—lung cancer	3.53e-06	2.12e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PIK3CD—lung cancer	3.35e-06	2.01e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PIK3CA—lung cancer	3.31e-06	1.99e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ALB—lung cancer	3.3e-06	1.99e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—AKT1—lung cancer	3.2e-06	1.92e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PIK3CB—lung cancer	2.92e-06	1.75e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PTGS2—lung cancer	2.89e-06	1.74e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—AKT1—lung cancer	2.71e-06	1.63e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PTEN—lung cancer	2.52e-06	1.52e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—EP300—lung cancer	2.4e-06	1.45e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PIK3CA—lung cancer	1.78e-06	1.07e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—AKT1—lung cancer	1.45e-06	8.73e-06	CbGpPWpGaD
